Detroit, MINCT06724016Now EnrollingIRB Ready

Advanced or Metastatic Solid Tumors Clinical Trial in Detroit, MI

Access cutting-edge advanced or metastatic solid tumors treatment through this clinical trial at a research site in Detroit. Study-provided care at no cost to qualified participants.

Sponsored by Hanmi Pharmaceutical Company Limited

Quick Self-Assessment

See if you qualify for this Detroit location

Preparing your pre-screening questions…

Expert Care in Detroit

Access advanced or metastatic solid tumors specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related advanced or metastatic solid tumors treatment provided free

Apply for This Detroit Location

Check if you qualify for this advanced or metastatic solid tumors clinical trial in Detroit, MI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Detroit

    Convenient for MI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Detroit site if eligible
  4. 4Begin participation

About This Advanced or Metastatic Solid Tumors Study in Detroit

This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of HM16390, as a single agent and in combination with pembrolizumab to assess safety, tolerability, MTD, RP2D, PK, and efficacy in patients with advanced or metastatic solid tumors. Dose-Escalation Part is planned to establish the MTD or RDs for the randomized Dose-Ranging Part. Based on the results of the Dose-Escalation Part, additional eligible subjects will be randomized 1:1 into each dose level. After a comprehensive review of available data from both Dose-Escalation Part and Dose-Ranging Part, the RDEs to be tested in the Dose-Expansion Part are determined. Dose-Expansion Part is designed to assess the potential efficacy of HM16390 as a single agent and in combination with pembrolizumab when administered at the RDEs to subjects in indication-specific expansion cohorts.

Sponsor: Hanmi Pharmaceutical Company Limited

Who Can Participate

Inclusion Criteria

Have a histologically and/or cytologically confirmed advanced or metastatic solid tumor and have failed or are intolerant to standard therapy with clinical benefit.
Patients in the Dose-Escalation Part must have evaluable or measurable disease at baseline and the patients for Dose-Ranging and Dose-Expansion Part must have at least one measurable lesion at baseline by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days before allocation or randomization.
Age of 18 years or older (or country's legal age of majority if the legal age was \>18 years)
Adequate renal function.
Adequate hematologic function.
Adequate liver function. Key

Exclusion Criteria

Received prior treatment with agent targeting the IL-2, IL-7, or IL-15 receptors, or related to mode of action of HM16390.
Known active CNS metastases and/or carcinomatous meningitis.
History of severe toxicities associated with a prior immunotherapy.
Any prior treatment-related (i.e. chemotherapy, immunotherapy, radiotherapy) clinically significant toxicities that have not resolved to Grade ≤ 1 per NCI-CTCAE version 5.0 or prior treatment-related toxicities that are clinically unstable and clinically significant at time of enrollment.
Has ongoing or suspected autoimmune disease.
Known active and clinically significant bacterial, fungal or viral infection including known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, immunocompromised patients.
History of chronic liver disease or evidence of hepatic cirrhosis.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Detroit?

Yes, this clinical trial (NCT06724016) has an active research site in Detroit, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced or Metastatic Solid Tumors Treatment Options in Detroit, MI

If you're searching for advanced or metastatic solid tumors treatment options in Detroit, MI, this clinical trial (NCT06724016) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Detroit research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced or metastatic solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced or metastatic solid tumors clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Detroit, MI

See all advanced solid tumors clinical trials recruiting in Detroit — not just this study.

Browse Advanced Solid Tumors Trials in Detroit →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAlzheimers Disease TrialsEssential Tremor TrialsAnkylosing Spondylitis TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Detroit?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Detroit, MI